BEIJING, March 1, 2016 /PRNewswire/ -- China Biologic
Products, Inc. (NASDAQ: CBPO)
("China Biologic" or the "Company"), a leading plasma-based
biopharmaceutical company in China, today announced that Warburg Pincus
Private Equity X, L.P. ("WP X") and Warburg Pincus X Partners, L.P.
(together with WP X, the "Selling Stockholders") agreed to sell
3,500,000 shares of the Company's common stock in an underwritten
public offering. China Biologic will not sell any shares in the
offering and it will not receive any proceeds from the sale of the
shares. Closing of the offering is expected to occur on or about
March 7, 2016, subject to customary
closing conditions. The total number of shares of common stock
outstanding will not change as a result of this offering.
The shares to be sold in this offering represent approximately
13.2 percent of the Company's current outstanding shares of common
stock.
Morgan Stanley & Co. International plc is acting as the sole
underwriter for the offering.
The offering is being made pursuant to an effective shelf
registration statement. The offering may be made only by means of a
prospectus supplement and the accompanying prospectus, copies of
which may be obtained by sending a request to Morgan Stanley,
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014, United States of America, or by calling
1-866-718-1649, or by email at prospectus@morganstanley.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any of the securities, nor shall
there by any sale of these securities, in any state in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities law of any such state.
About China Biologic Products, Inc.
China Biologic Products, Inc. (NASDAQ: CBPO), is a leading fully
integrated plasma-based biopharmaceutical company in China. The Company's products are used as
critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and
immune-deficiency related diseases. China Biologic is headquartered
in Beijing and manufactures over
20 different dosage forms of plasma products through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The
Company also has an equity investment in Xi'an Huitian Blood
Products Co., Ltd. The Company sells its products to hospitals,
distributors and other healthcare facilities in China. For additional information, please see
the Company's website www.chinabiologic.com.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements about the
proposed offering and the use of the offering proceeds that involve
risks and uncertainties. Any forward-looking statements and all
other statements that may be made in this news release that are not
historical facts are subject to a number of risks and
uncertainties, and actual results may differ materially. Specific
risks include stock market conditions and our ability to complete
the offering on acceptable terms. Please refer to China
Biologic filings with the SEC for more information on
the risk factors that could cause our actual results to differ. The
Company assumes no obligation and does not intend to update these
forward-looking statements, except as required by law.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/china-biologic-announces-secondary-offering-of-common-stock-300229134.html
SOURCE China Biologic Products, Inc.